tbuckley/cabot-search huggingface dataset:
Absence of microRNA-155 protects against adverse cardiac inflammation and hypertrophy during pressure overload and prevents heart failure
Authors: B Schroen, M Corsten, W Verhesen, L De Windt, Y. M Pinto, S Zacchigna, T Thum, Peter Carmeliet, Anna-Pia Papageorgiou, Stephane Heymans
Journal: Cardiovascular Research (2012)
Association Between Continued Cannabis Use and Risk of Relapse in First-Episode Psychosis
Authors: Tabea Schoeler, Natalia Petros, Marta Di Forti, Jean-Baptiste Pingault, Ewa Klamerus, Enrico Foglia, Amanda Small, Robin Murray, Sagnik Bhattacharyya
Journal: JAMA Psychiatry (2016)

Cannabis use after first-episode psychosis is associated with poor outcomes, but the causal nature of this association is unclear.To examine the precise nature of the association between continued cannabis use after the onset of psychosis and risk of relapse of psychosis.This prospective cohort study followed up for at least 2 years after the onset of psychosis 220 patients who presented to psychiatric services in South London, England, from April 12, 2002, to July 26, 2013, with first-episode psychosis. Longitudinal modeling (fixed-effects analysis, cross-lagged path analysis) was used to examine whether the association between changes in cannabis use and risk of relapse over time is the result of shared vulnerability between psychosis and cannabis use, psychosis increasing the risk of cannabis use (reverse causation), or a causal effect of cannabis use on psychosis relapse.Exposure to cannabis within the first and second years after onset of psychosis.The main outcome measure was relapse of psychosis, defined as subsequent hospitalization for psychosis. Effect of cannabis use status in the first year (Ct1) and second year (Ct2) and pattern of cannabis use continuation in the first year and second year were modeled for risk of relapse in the first year (Rt1) and risk of relapse in the second year (Rt2) after psychosis onset.A total of 220 patients with first-episode psychosis were included in the analysis (mean [SD] age, 28.62 [8.58] years; age range, 18-65 years; 90 women [40.9%] and 130 men [59.1%]). Fixed-effects models that adjusted for time-variant (other illicit drug use, antipsychotic medication adherence) and time-invariant (eg, genetic or premorbid environment) unobserved confounders revealed that there was an increase in the odds of experiencing a relapse of psychosis during periods of cannabis use relative to periods of no use (odds ratio, 1.13; 95% CI, 1.03-1.24). Change in the pattern of continuation significantly increased the risk (odds ratio, 1.07; 95% CI, 1.02-1.13), suggesting a dose-dependent association. Cross-lagged analysis confirmed that this association reflected an effect of cannabis use on subsequent risk of relapse (Ct1→Rt2: β = 0.44, P = .04) rather than an effect of relapse on subsequent cannabis use (Rt1→Ct2: β = -0.29, P = .59).These results reveal a dose-dependent association between change in cannabis use and relapse of psychosis that is unlikely to be a result of self-medication or genetic and environmental confounding.
Association of ABO blood type A and stage IV disease with venous thromboembolism in pancreatic cancer patients.
Authors: A. Shukla, S. Shukla, X. Zhou, M. J. Overman, S. Vadhan-Raj
Journal: Journal of Clinical Oncology (2010)

e14529 Background: Patients (pts) with pancreatic cancer (ca) are at high risk for venous thromboembolism (VTE). A known relationship between the ABO blood type and hemostasis exits. Non-O blood type pts are at increased risk for thrombosis, and recent data has shown that non-O blood type patients have an increased risk of developing pancreatic ca. Therefore, we wished to determine the relationship between ABO blood type and the incidence of VTE in pts with pancreatic ca. Methods: In this retrospective study, medical records of all pts with pancreatic ca (n=283) receiving active treatment at UT MDACC during the period from 7/1/2006 to 12/31/2006 were reviewed for the incidence of VTE from the date of their diagnosis until 6 months after the end of the study period. Data collected included demographics, ABO blood group, body mass index, metastatic disease, smoking status, and diabetes mellitus at the time of diagnosis. All VTE episodes were confirmed by radiologic studies. Univariate and multivariate logistic regression models were built to identify the independent risk factors for VTE. Results: Of the 283 pts, blood group data was available for 199 pts. The median age was 62 years (range: 15-87) and 45% were females. During the study period [median follow-up 16 months (range: 6-228)], 40 pts (20%) out of 199 developed VTE. Blood type A and metastatic status were significantly associated with VTE as shown below. In the univariate analysis no other variables were statistically significant. Multivariate logistic regression showed that blood group (A vs. non-A, odds ratio 3.0, 95%CI: 1.4-6.6, p=0.005) and metastatic disease [yes vs. no, 4.9(1.6-14.6), p=0.005] were statistically associated with the risk of VTE. Conclusions: ABO blood type A and the presence of metastatic disease at diagnosis are both significantly associated with the risk of VTE in pancreatic ca pts and should be considered for identifying high risk pts for thromboprophylaxis. Blood group A type Blood group non-A type Metastatic disease (stage IV) Nonmetastatic disease VTE (n = 40) 29 (73%) 11 (27%)* 36 (90%) 4 (10%)** No VTE (n = 159) 73 (46%) 86 (54%) 102 (64%) 57 (36%) * p =0.003. ** p= 0.002, chi-square test. No significant financial relationships to disclose.
Outcomes of progression on surveillance for clinical stage I nonseminomatous germ cell tumours (NSGCT).
Authors: Robert James Hamilton, Madhur Nayan, Lynn Anson-Cartwright, Philippe L. Bedard, Malcolm Moore, Peter W. M. Chung, Padraig Richard Warde, Joan Sweet, Martin O'Malley, Eshetu G. Atenafu, Michael A. S. Jewett
Journal: Journal of Clinical Oncology (2015)

377 Background: Active surveillance (AS) is universally accepted for clinical stage (CS) IA and favoured by most centers for CSIB. Patients progressing on AS are typically treated with chemotherapy, but there is no consensus. We describe patterns and mode of detection of progression and treatment of progression in our NSGCT AS cohort. Methods: From Dec 1980 to Aug 2011, 466 CSI NSGCT patients were managed with AS and 133 (28%) had disease progression while on AS. Treatment upon progression was physician choice but based on site of progression (e.g. retroperitoneum vs. extra-retroperitoneal), size or multifocality, and markers (S0 or stable, low level S1 vs. ≥ S1). Mode of detection of progression, characteristics at progression and primary treatment of progression (chemotherapy vs. retroperitoneal lymphadenectomy (RPLND)) were explored. Multivariate logistic regression was used to explore factors associated with receipt of more than one therapy in treatment of progression after surveillance. Results: Median time to progression was 7.3 months and detected by routine imaging (47%), routine serum tumour markers (37%), or both (12%). Progression most frequently occurred in the retroperitoneum (67%). Following progression, first-line treatment was chemotherapy for 71 (53%), RPLND for 51 (38%) and 11 (8.3%) underwent other therapy. In 59%, only one modality of treatment was required: chemotherapy only in 42/71 (59%); RPLND only in 36/51 (71%). For those treated with chemotherapy, pure embryonal carcinoma in the orchiectomy pathology (OR 0.11; p=0.05) was inversely associated with requiring further therapy. For those treated with RPLND, elevated markers pre-RPLND (OR 7.31; p=0.01) was associated with requiring further therapy. Overall, a second relapse occurred in 25/133 (19%) patients. With a median follow-up of 8.2 years, there were 5 deaths from testis cancer (3.8% of AS progressors; only 1.1% of overall AS cohort). Conclusions: The majority of patients progressing on surveillance do so in the retroperitoneum and within the first year. Of those that progress, most will achieve complete response with single modality treatment. In particular, RPLND can be utilized as monotherapy in select cases.
Gene expression profiling of glioblastoma (GBM) in an homogeneous treated population: Correlation with immunohistochemistry, radiology, clinical outcome, and response to therapy—A multicenter study from the GLIOCAT group, Marato TV3 2012, project 665/c/2013.
Authors: Carmen Balana, Francesc Alameda, Núria de la Iglesia, Jaume Capellades, Maria Martinez-Garcia, Estela Pineda, Teresa Ribalta, Sonia del Barco, Oscar Gallego, Oriol Arpi, Natalia Garcia, Carlos Mesia, Cristina Carrato, Sira Domenech, Eugenia Verger, Teresa Pujol, Laura Oleaga, Angels Camins, Raquel Lopez, Cristian De Quintana
Journal: Journal of Clinical Oncology (2016)

e13515 Background: Molecular alterations in GBM, might better explain than morphology or clinical factors, differences in outcome and response to treatment. Multiple data integration an homogeneous treatment of studied patients (p) is essential to obtain conclusive results. The objective of the GLIOCAT Group was to collect clinical data, MRI images, tissue and genomic information of an equally treated group of newly diagnosed p to conduct a multidimensional study with diverse pre-planned objectives. Methods: Collaborative study of 6 tertiary centers of Catalonia that shared clinical data of GBMp that were treated after surgery with the standard Stupp’s regimen, between 2005 and 2014. Formalin-Fixed Paraffin-Embedded (FFPE) samples of each case have been collected. We assessed MGMT status if previously not done, and constructed several Tissue Microarrays (TMA) for immunohistochemistry analysis from all cases. Best samples have been further processed for RNA extraction in order to proceed with RNA sequencing (RNAseq). In parallel, pre and immediate post-surgical MRIs have been uploaded to a web-based platform accessible to all radiologists at their own working place. Results: Four hundred and thirty-twopatients have been included. Sample tissues were available from 309p and basal radiology from 302p (plus immediate post surgical MRI from 220p). Uploaded radiology sequences are being classified for subsequent study. A reproducibility test on MGMT testing among centers has been performed before continuing the study (kappa index 0.523 p = 0.000). Seventeen TMAs (4 cores per p) have been constructed and 273 MGMT tests have been done so far. A test of viability of RNAseq on FFPE samples has been done on 4 paired cases that had both FFPE and fresh frozen samples available. Results showed the adequacy and reliability of RNAseq in FFPE samples. Conclusions: First clinical results will be presented at this meeting. The study is ongoing..
P0633 : Association of hepatitis B virus genetic diversity with tenofovir disoproxil fumarate response rates in immune tolerant chronic hepatitis B patients
Authors: J. Lara, H. Thai, K. Kitrinos, G. Xia, A. Gaggar, M. Paulson, L. Ganova-Raeva, Y. Khudyakov
Journal: Journal of Hepatology (2015)
Liver injury from herbal and dietary supplements
Authors: Victor J. Navarro, Ikhlas Khan, Einar Björnsson, Leonard B. Seeff, Jose Serrano, Jay H. Hoofnagle
Journal: Hepatology (2016)

Herbal and dietary supplements (HDS) are used increasingly both in the United States and worldwide, and HDS-induced liver injury in the United States has increased proportionally. Current challenges in the diagnosis and management of HDS-induced liver injury were the focus of a 2-day research symposium sponsored by the American Association for the Study of Liver Disease and the National Institutes of Health. HDS-induced liver injury now accounts for 20% of cases of hepatotoxicity in the United States based on research data. The major implicated agents include anabolic steroids, green tea extract, and multi-ingredient nutritional supplements. Anabolic steroids marketed as bodybuilding supplements typically induce a prolonged cholestatic but ultimately self-limiting liver injury that has a distinctive serum biochemical as well as histological phenotype. Green tea extract and many other products, in contrast, tend to cause an acute hepatitis-like injury. Currently, however, the majority of cases of HDS-associated liver injury are due to multi-ingredient nutritional supplements, and the component responsible for the toxicity is usually unknown or can only be suspected. HDS-induced liver injury presents many clinical and research challenges in diagnosis, identification of the responsible constituents, treatment, and prevention. Also important are improvements in regulatory oversight of nonprescription products to guarantee their constituents and ensure purity and safety. The confident identification of injurious ingredients within HDS will require strategic alignments among clinicians, chemists, and toxicologists. The ultimate goal should be to prohibit or more closely regulate potentially injurious ingredients and thus promote public safety. (Hepatology 2017;65:363-373).
Impact of maternal nutrition in pregnancy and lactation on offspring gut microbial composition and function
Authors: Derrick M. Chu, Kristen M. Meyer, Amanda L. Prince, Kjersti M. Aagaard
Journal: Gut Microbes (2016)

Evidence supporting the Developmental Origins of Health and Disease Hypothesis indicates that maternal nutrition in pregnancy has a significant impact on offspring disease risk later in life, likely by modulating developmental processes in utero. Gut microbiota have recently been explored as a potential mediating factor, as dietary components strongly influence microbiota abundance, function and its impact on host physiology. A growing body of evidence has additionally indicated that the intrauterine environment is not sterile as once presumed, indicating that maternal-fetal transmission of microbiota may occur during pregnancy. In this article, we will review the body of literature that supports this emerging hypothesis, as well as highlight the work in relevant animal models demonstrating associations with maternal gestational nutrition and the offspring gut microbiome that may influence offspring physiology and susceptibility to disease.
An Individual Patient Supply Program for Ruxolitinib for the Treatment of Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF).
Authors: Giovanni Barosi, Mohan Agarwal, Sonja Zweegman, Wolfgang Willenbacher, Sima Pakstyte, Reinier Raymakers, Nathan Cantoni, Ankur Modi, Mahmudul Khan, Jose Ricardo Perez, Hans Hasselbalch, Jose Pablo Vargas Viveros, Camila C.G. Linardi, Heinz Gisslinger, Adelmo Henrique Daumas Gabriel, Francesca Palandri, David Lavie, Claire N Harrison
Journal: Blood (2012)
Treatment-specific risks of second malignancy and cardiovascular disease in Hodgkin lymphoma survivors.
Authors: Simone de Vries, Frederika A. van Nimwegen, Michael Schaapveld, Pieternella J. Lugtenburg, Augustinus D.G. Krol, Judith M. Roesink, John M. M. Raemaekers, Berthe M.P. Aleman, Flora Van Leeuwen
Journal: Journal of Clinical Oncology (2015)

9584 Background: Hodgkin lymphoma (HL) survivors are at increased risk to develop late treatment-related complications, including second malignant neoplasms (SMNs) and cardiovascular disease (CVD). Research to date has focused on separate risk estimates and therefore, we aimed to assess the combined risk of developing SMN and/or CVD. Methods: Our multicenter cohort comprised 2,480 5-year HL survivors, treated before age 51 between 1965 and 1995. CVD endpoints (coronary heart disease [CHD], cardiomyopathy and congestive heart failure [HF], and valvular heart disease) were assessed through general practitioners. Data on SMN were derived from linkage with the Netherlands Cancer Registry. Standardized incidence ratios (SIRs) were estimated to compare SMN and CVD risk with the general population. Cumulative incidences of SMN and/or CVD were calculated with death from other causes as competing risk. Treatment-specific risks of developing SMN and/or CVD were quantified using Cox regression analysis. Results: After a median follow-up of 22 years, we identified 874 SMNs and 1368 CVDs. 1246 patients developed ≥ 1 major event, of whom 276 developed both SMN and CVD. HL survivors had a 5.2-fold increased SIR of any SMN (95%CI: 4.8-5.6), compared to the general population, corresponding to 141 excess cases/10,000 person-years. The SIRs of CHD and HF were 3.5 and 7.8, respectively (95%CI: 3.2-3.9 and 6.8-8.8), resulting in 83 and 60 excess cases/10,000 person-years. After 40 years, at a median attained age of 60 years, the cumulative incidence of SMN or CVD was 73.3% (95%CI: 70.6-75.7), whereas 22.5% (95%CI: 19.8-25.3) of patients had developed both events. Both supradiaphragmatic RT (Hazard Ratio [HR]: 2.6, 95%CI: 2.1-3.1) and anthracycline-containing CT (HR: 1.5, 95%CI: 1.3-1.7) independently increased the risk of SMN and/or CVD. Supradiaphragmatic RT was associated with a strongly increased (HR: 4.4, 95%CI: 2.6-7.7) risk of developing both SMN and CVD. Conclusions: HL survivors experience a high disease burden during follow-up, with the cumulative incidence of SMN and/or CVD rising to 73% after 40 years from initial treatment. Supradiaphragmatic RT most strongly increased this risk.
Preliminary evaluation of accuracy of diffusion-weighted magnetic resonance imaging in preoperative nodal staging of rectal cancer.
Authors: K. Sato, T. Akasu, G. Iinuma, M. Miyake, S. Yamamoto, Y. Arai, N. Moriyama
Journal: Journal of Clinical Oncology (2010)

e14095 Background: We previously reported accuracy of high-resolution (HR) magnetic resonance imaging (MRI) in preoperative staging of rectal cancer (Ann Surg Oncol 2009). Especially, accurate nodal staging is essential for deciding treatment. The aim of this study was to evaluate whether an addition of diffusion-weighted (DW) MRI improve an accuracy of preoperative nodal staging for rectal cancer. Methods: Between April and December 2007, 40 patients with primary rectal cancer were examined with HRMRI and DWMRI using a 1.5-T or 3-T scanner and underwent radical surgery. Lymph node metastasis was assessed prospectively and classified according to the TNM system by pathologists blind to clinical information. A clinical fellow with 1-year experience of diagnostic radiology retrospectively reviewed HRMRI images and measured the short-axis diameters of the pelvic lymph nodes, and then HRMRI plus DWMRI images were evaluated. Patient-by-patient, receiver operating characteristic curve analyses were performed. Results: Of 18 patients with lymph node metastases, 17 had mesorectal and 5 had lateral pelvic node involvement (3, right; 2, left). Area under the receiver operating characteristic curves (AUCs) of HRMRI for mesorectal, right lateral pelvic, and left lateral pelvic nodes were 0.54 (95% confidence interval, 0.34–0.74), 0.49 (0.19–0.79), and 0.53 (0.19–0.88), respectively. AUCs of HRMRI plus DWMRI for mesorectal, right lateral pelvic, and left lateral pelvic nodes were 0.62 (0.44–0.81), 0.89 (0.76–1.0), and 0.96 (0.90–1.0), respectively. Conclusions: This study suggested that an addition of DWMRI to conventional HRMRI improved diagnositic accuracy of staging for both mesorectal and lateral pelvic lymph node metastases from rectal cancer. No significant financial relationships to disclose.
P0697 : Interplay between virus-specific and apoptotic epitope-specific CD8+ T cells in chronic hepatitis C virus
Authors: H. Martini, A. Citro, C. Martire, D. Accapezzato, G. Labbadia, E.N. Cavallari, G. D’Ettorre, L. Calvo, F. Rizzo, M. Severa, E.M. Coccia, V. Barnaba
Journal: Journal of Hepatology (2015)
Non-IG Aberrations of FOXP1 in B-Cell Malignancies Result in an Aberrant Expression of N-Truncated FOXP1 Isoforms.
Authors: Iwona Wlodarska, Leila Rouhi, Julio Finalet Ferreiro, Thomas Tousseyn, Natalie Put, Eugenia Haralambieva, Carlos Graux, Brigitte Maes, Carmen Vicente, Peter Vandenberghe, Jan Cools
Journal: Blood (2012)
Large airways nodularity secondary to tracheobronchopathia osteochondroplastica
Authors: John P Corcoran, John M Wrightson, Alastair J Moore, Fergus V Gleeson, Annemarie Sykes
Journal: Thorax (2016)

A 74-year-old retired librarian was referred for assessment after a full-body CT, performed to investigate a 3-month history of persistent nausea and weight loss, incidentally identified a 10 mm left lower lobe nodule alongside small volume nodularity seen throughout the trachea and proximal main bronchi (figure 1). There was no previous thoracic imaging for comparison. She had a five pack-year smoking history and reported no preceding respiratory disease or symptoms. Her medical background was otherwise unremarkable. She appeared well in clinic; physical examination, basic spirometry (FEV1 131%, FVC 133% predicted) and flow-volume loops were normal. A subsequent positron emission tomography-CT scan demonstrated physiological uptake only and no areas of abnormality. Following MDT discussion it was recommended to obtain histopathological samples via bronchoscopy given the history of unexplained weight loss and extent of the nodularity within the large airways.



Figure 1 
CT images demonstrating irregular nodularity …
Use of a Roth Net Platinum Universal Retriever for the endoscopic management of a large symptomatic gallstone causing Bouveret’s syndrome
Authors: Ankur Jindal, Cyriac Philips, Kapil Jamwal, Shiv Sarin
Journal: Endoscopy (2016)

A 65-year-old woman, who was diagnosed with extrahepatic portal vein thrombosis, portal biliopathy, and gallstone disease, presented with multiple episodes of vomiting associated with abdominal pain after meals, with no overt gastrointestinal bleed or jaundice.
A study of informed consent (IC), age, and cognitive function (CF) among advanced cancer patients (acp) in phase I trials
Authors: F. J. Hlubocky, E. Larson, G. Sachs, C. K. Daugherty
Journal: Journal of Clinical Oncology (2007)

6548 Background: Ethical concerns exist about acps’ ability to provide adequate informed consent (IC) for phase I trials. While cognitive impairment (CI) among acp is well-recognized due to multiple factors, e.g., previous effects of chemotherapy, age, psychological status, the prevalence of CI among acp in phase I trials has never been described. Methods: Acp CF was assessed using a neuropsychological battery of instruments: Hopkins Verbal Learning (HVLT); Verbal Fluency; Mini-Cognitive Assessment; Trail-making (Parts A&amp; B); Boston Naming (short); WAIS subtests (Comprehension and Digit Span). Acp underwent semi-structured interviews to evaluate elements of IC, and completed the FACT-COG and the Hospital Anxiety and Depression Scale (HADS). Results: To date, a total of 34 acp enrolling in Phase I trials have been studied. Median age: 63y (range: 38–81y); 77% male; 77% Caucasian; 67% &gt; HS education. Regarding IC understanding: Only 20% of responding acp correctly identified the purpose of Phase I trials; all subjects could recall risks of side effects, correctly stated they could refuse trial participation, and stated they could withdraw at anytime; 53% believed the trial was their only option. Older acp (&gt;age 55y) were less likely to correctly describe the research purpose of the trial (29% v. 71% p=0.02). Older acp had measurable deficits in CF: Boston Naming (14±0.9 v.15±0.3, p=0.09); HVLT Total Recall (14±2 v.26±6, p&lt;0.00) and Discrimination Index (7.5±3 v.11±1, p=0.03); Digit Span-Backwards (4±2 v.7±2, p&lt;0.00); Trail-making B (244±64 v.188±51, p=0.04). While there were no differences in perceived CI (95±18 v.101±19, p=0.5) or impact on quality of life (25±7 v. 27±5, p=0.5), both groups had scores well below prior reported means. Older acp tended to report depressive symptoms more than younger acp (8±2 v.6±1, p=0.07). Conclusions: Our data suggest that CF may play a role in acp understanding of IC for clinical trials, especially among the elderly. Further research is needed, given ethical concerns regarding elderly acp in clinical trials of experimental agents who may have CI. No significant financial relationships to disclose.